1 / 12

Characteristics of included studies

Characteristics of included studies. João Costa, et al. BMJ; 2006;332:1115-1124. Event rate for major coronary events in primary prevention trials (mean weighted follow-up 4.5 years). João Costa, et al. BMJ; 2006;332:1115-1124.

keisha
Télécharger la présentation

Characteristics of included studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Characteristics of included studies João Costa, et al. BMJ; 2006;332:1115-1124

  2. Event rate for major coronary events in primary prevention trials (mean weighted follow-up 4.5 years) João Costa, et al. BMJ; 2006;332:1115-1124

  3. Event rate for major coronary events in secondary prevention trials (mean weighted follow-up 5.1 years) João Costa, et al. BMJ; 2006;332:1115-1124

  4. Primary prevention of major coronary events João Costa, et al. BMJ; 2006;332:1115-1124

  5. Secondary prevention of major coronary events João Costa, et al. BMJ; 2006;332:1115-1124

  6. Secondary prevention of coronary heart disease death João Costa, et al. BMJ; 2006;332:1115-1124

  7. Secondary prevention of non-fatal myocardial infarction João Costa, et al. BMJ; 2006;332:1115-1124

  8. Secondary prevention of myocardial revascularisation procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) João Costa, et al. BMJ; 2006;332:1115-1124

  9. Primary prevention of major coronary events João Costa, et al. BMJ; 2006;332:1115-1124

  10. Number needed to treat and benefit for 1000 patients João Costa, et al. BMJ; 2006;332:1115-1124

  11. Secondary prevention of stroke João Costa, et al. BMJ; 2006;332:1115-1124

  12. Change in blood lipid concentrations HDL-C=high density lipoprotein cholesterol; LDL-C=low density lipoprotein cholesterol (no data for total cholesterol were available in VA-HIT) João Costa, et al. BMJ; 2006;332:1115-1124

More Related